ArticleMolecular neurobiology2026
A53T α-Synuclein Expression is Associated with Altered Dopaminergic-Like Differentiation and Reduced DNA Topoisomerase IIβ Levels in an In Vitro Model of Parkinson's Disease.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DNA Topoisomerase IIβ Suppresses Microglial Inflammatory Cytokine Release: A Potential Regulator of Neuroinflammation.Neurochemical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The study explores the interaction between topoisomerase IIβ (topo IIβ) and α-synuclein aggregation in Parkinson's disease (PD) using an in vitro model overexpressing A53T mutant α-synuclein, revealing key pathological features. The overexpression of A53T mutant α-synuclein was associated with impaired neuronal differentiation, accompanied by delayed neurite outgrowth and reduced levels of MAP2 and NF-L. Transcriptomic study during differentiation revealed substantial gene expression changes, with 57 of 84 PD-associated genes exhibiting differential regulation on days 8 and 12. Dopaminergic markers like TH, BDNF, NR4A2 (Nurr1), PINK1, and SYNGR3 were notably upregulated in differentiated cells, whereas A53T mutant α-synuclein overexpression was associated with significant downregulation of 22 genes associated with PD, including TH, NR4A2, BDNF, and PINK1, suggesting alterations in neuroprotective signaling pathways. Topo IIβ expression diminished during differentiation in the presence of pathogenic α-synuclein and was associated with changes in the proposed topo IIβ-Nurr1 regulatory axis potentially contributing to early neurodevelopmental abnormalities and dopaminergic vulnerability observed in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.